These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33805342)

  • 41. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy.
    Um W; Park J; Ko H; Lim S; Yoon HY; Shim MK; Lee S; Ko YJ; Kim MJ; Park JH; Lim DK; Byun Y; Kwon IC; Kim K
    Biomaterials; 2019 Dec; 224():119494. PubMed ID: 31542518
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor.
    Ma L; Yu P; Veerendra B; Rold TL; Retzloff L; Prasanphanich A; Sieckman G; Hoffman TJ; Volkert WA; Smith CJ
    Mol Imaging; 2007; 6(3):171-80. PubMed ID: 17532883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enzyme-Triggered Disassembly of Polymeric Micelles by Controlled Depolymerization via Cascade Cyclization for Anticancer Drug Delivery.
    Park J; Jo S; Lee YM; Saravanakumar G; Lee J; Park D; Kim WJ
    ACS Appl Mater Interfaces; 2021 Feb; 13(7):8060-8070. PubMed ID: 33576220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN.
    Liu Z; Yan Y; Chin FT; Wang F; Chen X
    J Med Chem; 2009 Jan; 52(2):425-32. PubMed ID: 19113865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ROS-Responsive Polymeric Micelle for Improving Pesticides Efficiency and Intelligent Release.
    Li R; Xie H; Zhang C; Sun Y; Yin H
    J Agric Food Chem; 2020 Aug; 68(34):9052-9060. PubMed ID: 32806117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
    Powell Gray B; Kelly L; Ahrens DP; Barry AP; Kratschmer C; Levy M; Sullenger BA
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4761-4766. PubMed ID: 29666232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Light-Responsive Nanoparticles for Highly Efficient Cytoplasmic Delivery of Anticancer Agents.
    Wang Y; Deng Y; Luo H; Zhu A; Ke H; Yang H; Chen H
    ACS Nano; 2017 Dec; 11(12):12134-12144. PubMed ID: 29141151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactive oxygen species-responsive amino acid-based polymeric nanovehicles for tumor-selective anticancer drug delivery.
    Yuan Y; Zhao L; Shen C; He Y; Yang F; Zhang G; Jia M; Zeng R; Li C; Qiao R
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110159. PubMed ID: 31753404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aortic plaque-targeted andrographolide delivery with oxidation-sensitive micelle effectively treats atherosclerosis via simultaneous ROS capture and anti-inflammation.
    Wu T; Chen X; Wang Y; Xiao H; Peng Y; Lin L; Xia W; Long M; Tao J; Shuai X
    Nanomedicine; 2018 Oct; 14(7):2215-2226. PubMed ID: 29964220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ROS-Activated Ratiometric Fluorescent Polymeric Nanoparticles for Self-Reporting Drug Delivery.
    Zhang M; Song CC; Su S; Du FS; Li ZC
    ACS Appl Mater Interfaces; 2018 Mar; 10(9):7798-7810. PubMed ID: 29424527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source.
    Yue C; Yang Y; Zhang C; Alfranca G; Cheng S; Ma L; Liu Y; Zhi X; Ni J; Jiang W; Song J; de la Fuente JM; Cui D
    Theranostics; 2016; 6(13):2352-2366. PubMed ID: 27877240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer.
    Wu W; Chen M; Luo T; Fan Y; Zhang J; Zhang Y; Zhang Q; Sapin-Minet A; Gaucher C; Xia X
    Acta Biomater; 2020 Feb; 103():259-271. PubMed ID: 31846803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A positive feedback strategy for enhanced chemotherapy based on ROS-triggered self-accelerating drug release nanosystem.
    Hu JJ; Lei Q; Peng MY; Zheng DW; Chen YX; Zhang XZ
    Biomaterials; 2017 Jun; 128():136-146. PubMed ID: 28325685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ditelluride-Bridged PEG-PCL Copolymer as Folic Acid-Targeted and Redox-Responsive Nanoparticles for Enhanced Cancer Therapy.
    Pang Z; Zhou J; Sun C
    Front Chem; 2020; 8():156. PubMed ID: 32181244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy.
    Yoo J; Sanoj Rejinold N; Lee D; Jon S; Kim YC
    J Control Release; 2017 Oct; 264():89-101. PubMed ID: 28842316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect.
    Qin B; Liu L; Wu X; Liang F; Hou T; Pan Y; Song S
    Acta Biomater; 2017 Dec; 64():211-222. PubMed ID: 28963017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.